What the literature shows
The CJC-1295 research record: GH, IGF-1, and where the evidence stops
Mechanism, the human pharmacokinetic studies, the animal work, and an honest map of what controlled trials have not measured.
CJC-1295 review: a reading of the literature
CJC-1295 entered the literature in 2005, when a series of hGRF(1-29)-albumin bioconjugates was screened for a GHRH analog that could resist clearance and last in plasma [2]. The lead candidate combined four substitutions that block dipeptidylpeptidase-IV cleavage, deamidation, and oxidation with a covalent link to serum albumin. In rats it produced a 4-fold increase in GH area-under-the-curve over two hours versus unconjugated hGRF(1-29), remained detectable in plasma beyond 72 hours, and was stable against DPP-IV in vitro [2].
Human characterization followed in 2006. Two studies in healthy volunteers established the GH/IGF-1 kinetics that still define the compound [1] [3]. The picture is consistent: a single subcutaneous dose drives a dose-dependent, multi-day rise in GH and IGF-1, and the pituitary's pulsatile rhythm survives the sustained stimulation. The review-level synthesis is current — a 2024/2025 Nature Reviews Endocrinology review of GHRH and its synthetic analogues situates CJC-1295 alongside sermorelin and tesamorelin and describes the receptor signaling and the rationale for long-acting design [14].
How CJC-1295 works
CJC-1295 binds the GHRH receptor, a class B G-protein-coupled receptor on pituitary somatotrophs. Activation runs through Gs and adenylate cyclase to raise cAMP, drives PKA and CREB-mediated transcription of the GH gene, and stimulates synthesis and pulsatile release of growth hormone [1]. Released GH reaches the liver, engages the GH receptor, and through JAK2/STAT5 signaling raises IGF-1 — the downstream hormone that mediates much of GH's anabolic activity.
The design choices are what give the molecule its duration. The four substitutions on the hGRF(1-29) backbone block the proteases that clear native GHRH within minutes [2]. In the DAC variant, the maleimidopropionyl linker undergoes Michael addition with the free thiol on Cys34 of serum albumin, forming a covalent peptide-albumin conjugate whose plasma residence approaches that of albumin itself [2]. The effective circulating species is the much larger peptide-albumin complex, and its slow clearance is why a single dose elevates the GH/IGF-1 axis for days [1].
CJC-1295 benefits: what the GH/IGF-1 findings show
Among CJC-1295 benefits discussed in the literature, the documented effects are pharmacokinetic, not clinical outcomes. In healthy adults, 30 or 60 µg/kg produced 2- to 10-fold increases in mean plasma GH for six days or more and 1.5- to 3-fold increases in IGF-1 for 9 to 11 days; multiple doses kept IGF-1 above baseline up to 28 days [1]. In healthy men, a single 60 or 90 µg/kg dose raised basal GH about 7.5-fold, mean GH about 46%, and IGF-1 about 45% one week later, with pulsatility intact [3].
A proteomic study in 11 healthy young men found that CJC-1295 reproducibly shifted the serum protein profile — apolipoprotein A1 and a transthyretin isoform fell, an albumin fragment and immunoglobulin species rose — and that the immunoglobulin/albumin-fragment signal correlated linearly with IGF-1, identifying candidate biomarkers of GH/IGF-1 axis activation [5]. These are measurable activations of the axis. They are not evidence of muscle gain, fat loss, or any clinical benefit; no controlled CJC-1295 trial reports body-composition outcomes [1] [3].
What to expect when taking CJC-1295?
Published human data describe dose-dependent multi-day elevation of GH and IGF-1 after a single subcutaneous dose [1] [3]. Broader physiological expectations in healthy adults — strength, body composition, recovery, aging markers — are not established by controlled trials. The honest summary is that the literature characterizes a hormone-axis response and stops there.
The animal evidence
The clearest demonstration that CJC-1295's long action is sufficient for physiology comes from GHRH-knockout mice. Given 2 µg once every 24 hours, CJC-1295 fully normalized body weight and length; dosing every 48 to 72 hours was progressively less effective, and treatment raised pituitary GH mRNA [4]. The once-daily schedule restored GH-axis-dependent growth in animals that could not make their own GHRH — a direct readout of the analog's durability.
The foundational rat work [2] and the GHRH-knockout-mouse normalization [4] are the load-bearing animal studies; both are flagged as preclinical, because their endpoints (GH AUC, normalized growth) are animal-model readouts, not human outcomes.
CJC-1295 among GHRH analogs
As a GHRH analog, CJC-1295 sits in a class that includes sermorelin (GHRH 1-29) and tesamorelin, the closest approved-drug comparator, which is approved for HIV-associated lipodystrophy [14]. The class shares a target — the GHRH receptor — and a rationale: stimulate the body's own pulsatile GH output rather than replace GH directly. What distinguishes CJC-1295 within the class is the albumin-conjugation strategy that buys a multi-day half-life [2]. The 2025 Nature Reviews Endocrinology review describes this long-acting design across the GHRH-analog family [14], and a 2026 gerontology review situates GH-axis peptides in the healthy-aging research conversation [15] — research framing, not endorsement.
The analytical record is its own line of evidence. CJC-1295 has been definitively identified by high-resolution LC-MS/MS as the active ingredient in a seized 'GHRH' preparation [6], and reviews of GHRH-analog detection document the assays used in anti-doping [12] [13].
CJC-1295 side effects: reported and theoretical concerns
CJC-1295 side effects in the published and theoretical record stem mainly from sustained stimulation of the GH/IGF-1 axis. Recognized GH-axis effects include fluid retention and edema and effects on insulin sensitivity. Epidemiology links higher circulating IGF-1 to a modestly increased risk of certain cancers, a theoretical concern whenever the axis is chronically elevated. FDA briefing materials for the 2024 Pharmacy Compounding Advisory Committee cited immunogenicity and other safety concerns for GH secretagogues including CJC-1295.
Two facts of the development history belong on the record. The original long-acting DAC program (ConjuChem) was discontinued, and a Phase 2 trial in HIV-associated visceral obesity did not advance. A patient death during the development era is frequently cited in connection with the halted program, though a causal link to CJC-1295 was not established in the public record. None of these are settled safety conclusions in healthy adults — they are the documented and theoretical concerns a reader should weigh, and they are why the human evidence remains early.